Neisseria meningitidis

What is Meningococcal Disease?

Meningococcal (muh-nin-jo-cok-ul) disease is a serious bacterial illness that can lead to severe swelling of the tissues surrounding the brain and spinal cord (meningitis) or infection of the bloodstream (meningococcal septicemia or meningococcemia). Pneumonia (lung infection) also occurs, but is less common.

According to the Centers for Disease Control and Prevention (CDC), meningococcal bacteria spread through the exchange of respiratory and throat secretions like saliva or spit (e.g., by coughing, living in close quarters, kissing).


Anyone can get meningococcal disease but certain people are at increased risk, including:

  • Infants younger than 1 year old
  • Teens (adolescents) and young adults age 16-23 years old
  • College students
  • People with certain medical conditions that affect the immune system such as HIV
  • Microbiologists who routinely work with isolates of Neisseria meningitidis, the bacteria that cause
    meningococcal disease
  • People at risk because of an outbreak in their community
  • Individuals traveling to a country where meningococcal disease is epidemic or highly endemic
  • Military recruits

Even with treatment, about 10 to 15 out of 100 people with meningococcal disease will die from it. Of those who survive, up to 20% will suffer serious and permanent complications including brain damage, kidney damage, hearing loss, and amputation of arms, legs, fingers, or toes.

The Centers for Disease Control and Prevention has information about recent meningococcal outbreaks.


Early meningococcal disease symptoms are often similar to influenza (flu) which can cause a delay in
diagnosis and treatment. Symptoms usually progress very quickly and may include a combination of the following:

  • Fever
  • Headache
  • Stiff neck
  • Confusion
  • Nausea, vomiting
  • Exhaustion
  • Purplish rash

Death can happen in as little as 24-48 hours. People who experience these symptoms, especially if they are unusually sudden, progressive, or severe, should be examined as soon as possible by a healthcare professional.


Keeping up to date with recommended vaccines is the best way to protect against meningococcal disease. Three types of meningococcal vaccines are available in the US (MenACWY, MenB, MenABCWY).

CDC recommends routine MenACWY for:

  • All preteens at age 11-12 years
  • All teens at age 16 years (booster dose)
  • Children and adults at increased risk for meningococcal disease

CDC recommends routine MenB vaccine:

  • People age 10 years or older at increased risk for meningococcal disease

Teens and young adults (age 16-23 years) also may get a MenB vaccine.

CDC recommends MenABCWY vaccination as an option for:

  • People age 10 years or older who are getting MenACWY and MenB at the same visit

Talk to your healthcare professional if your teen missed getting MenACWY or if you are interested in MenB vaccination.

CDC recommends meningococcal vaccines for adults if they are at increased risk. This includes:

  • Certain medical conditions (talk to your healthcare professional for the appropriate schedule)
  • International travelers to areas where meningococcal disease is endemic
  • Scientists (and other jobs) Jobs working with the bacteria
  • Colle students
  • Military personnel
  • Increased risk due to a meningococcal disease outbreak


Meningococcal disease can be treated with antibiotics, but quick medical attention is extremely important to help reduce the risk of dying. Depending on how serious the infection is, people with meningococcal disease may need other treatments, including:

  • Breathing support
  • Low blood pressure medications
  • Surgery to remove dead tissue, caused by septicemia
  • Wound care for skin damaged, caused by septicemia

Even with treatment, one in 10 people infected with meningococcal disease will die. Up to one in five survivors will have long-term disabilities, such as loss of limb(s), deafness, nervous system problems, or brain damage.

Meningococcal Disease: Focus on Serogroup B

Why is serogroup B meningococcal disease of particular concern?

Serogroup B is unique because it is the most common cause of meningococcal disease in US adolescents and young adults.

Is serogroup B disease more severe than other serogroups?

  • Serogroup B meningococcal disease is of similar severity to disease caused by other serogroups.
  • Meningococcal disease, regardless of serogroup, is marked by rapid progression (typically hours, but occasionally days) from symptom onset to severe outcomes, even when it is treated quickly.
  • Even with rapid and appropriate treatment, is 1 in 10 will die.
  • Long-term complications will affect 1 in 5 survivors and include hearing loss, skin scarring, brain
    damage, kidney failure, and limb amputations among others.

Updated November 2023

Source: Centers for Disease Control and Prevention

Related Resources

June ACIP Meeting Updates Webinar Presenters
July 12, 2023 12:00 pm

Updates from June 2023 Advisory Committee on Immunization Practices (ACIP) Meeting

In this webinar, speakers discuss updates from the June 2023 Advisory Committee on Immunization Practices (ACIP) meeting. Hear about the latest updates regarding US vaccination recommendations for children, adolescents, and adults …

Learn More
Webinar - Updates from February 2023 Advisory Committee on Immunization Practices ACIP Meeting
March 22, 2023 12:00 pm

Updates from February 2023 Advisory Committee on Immunization Practices (ACIP) Meeting

In this recorded webinar, speakers discuss the latest updates regarding current US vaccination recommendations for children, adolescents, and adults, highlighting updates from the February 22-24, 2023, Advisory Committee on Immunization Practices meeting …

Learn More
Webinar - Plan Ahead: Vaccines Recommended for Travel
December 15, 2022 12:00 pm

Plan Ahead: Vaccines Recommended for Travel

In this webinar, speakers will discuss the geographic epidemiology and clinical manifestations of certain pathogens encountered during travel and summarize current ACIP recommendations for common travel vaccines. Speakers will also identify strategies for implementation of recommendations into clinical practice …

Learn More